<DOC>
	<DOCNO>NCT01368458</DOCNO>
	<brief_summary>This 12-week , 32-week follow-up , rater-blind , randomize control trial determine whether patient chronic schizophrenia schizoaffective disorder receive two different antipsychotic simultaneously significant change psychopathology follow conversion antipsychotic monotherapy . Additionally , effect conversion antipsychotic monotherapy assess neurocognitive test . The study conduct Clinical Research Evaluation Facility ( CREF ) , specialize research unit jointly operate Nathan S Kline Institute Psychiatric Research ( NKI ) Rockland Psychiatric Center ( RPC ) . Patients recruit regular in-patient unit RPC transfer CREF . Following baseline assessment , patient randomize continued antipsychotic polypharmacy treatment systematic conversion monotherapy . Conversion antipsychotic monotherapy assess across multiple domain psychopathology use Positive Negative Symptom Scale ( PANSS ) . The primary outcome measure PANSS total score . The secondary outcome measure time medication ( all-cause dropout ) . Mixed Model Repeated Measures ( MMRM ) test hypothesis conversion antipsychotic monotherapy show minimal change control group .</brief_summary>
	<brief_title>Conversion Antipsychotic Monotherapy</brief_title>
	<detailed_description>Background : Often , treatment resistant schizophrenia patient treat high dos , polypharmacy , antipsychotic , . There lack systematic evidence either practice , recommend treatment guideline . Often polypharmacy result dosages well recommended upper limit dosage . Recent study antipsychotic utilization , report approximately 10-60 % patient prescribe least two antipsychotic . Moreover , antipsychotic treatment carry substantial risk , include potential development tardive dyskinesia metabolic syndrome . Higher dos may expose patient adverse event consequence without additional therapeutic benefit . Clear benefit long-term treatment antipsychotic polypharmacy rarely report , void long term double blind , placebo control trial . Antipsychotic polypharmacy remain common , include patient receive atypical antipsychotic . To knowledge , one publish study systematic , randomize control conversion antipsychotic monotherapy patient chronic schizophrenia schizoaffective disorder receive atypical antipsychotic polypharmacy . Design : Hospitalized patient DSM-IV-TR schizophrenia schizoaffective disorder meeting follow criterion : ( 1 ) least two antipsychotic , ( 2 ) stable dosage least one month prior baseline , ( 3 ) baseline dosage least one antipsychotic least olanzapine 15 mg , ziprasidone 120 mg , quetiapine 500 mg , risperidone 4 mg , aripiprazole 10 mg , paliperidone 6 mg , dose clozapine , first generation antipsychotic &gt; 300 chlorpromazine equivalent . After baseline assessment , patient randomize conversion antipsychotic monotherapy one two antipsychotic continue combination antipsychotic treatment . Other psychotropics leave unchanged baseline , prescription new psychotropic permit , except lorazepam benztropine detail . If patient randomize conversion monotherapy , decision two baseline antipsychotic continue occur follow : 1 . If one clozapine , clozapine continue . 2 . In case : 1 . If one antipsychotic dose great noted dos , one continue . 2 . If dos great noted dos , flip coin determine continue , head equal one high alphabetic letter tail equal low .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patients age 1864 SCID DSMIVTR diagnosis schizophrenia schizoaffective disorder , confirm SCID , able give write informed consent stable dosage two antipsychotic least one month prior baseline . Lack capacity give inform consent ( capacity determine licensed member treatment team ) unstable medical illness use long act injectable preparation antipsychotic medication previous two month document failure previous dose reduction current treatment clozapine addition new psychotropic previous month patient severely assaultive clinical need one antipsychotic safe management</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>